UY31812A - Derivados de cinolina como inhibidores de csf-1 - Google Patents

Derivados de cinolina como inhibidores de csf-1

Info

Publication number
UY31812A
UY31812A UY0001031812A UY31812A UY31812A UY 31812 A UY31812 A UY 31812A UY 0001031812 A UY0001031812 A UY 0001031812A UY 31812 A UY31812 A UY 31812A UY 31812 A UY31812 A UY 31812A
Authority
UY
Uruguay
Prior art keywords
csf
inhibitors
manufacture
chemical compounds
relates
Prior art date
Application number
UY0001031812A
Other languages
English (en)
Inventor
Kevin Daly
Scott David
Ye Qing
David Del Valle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY31812A publication Critical patent/UY31812A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos químicos de la fórmula (I): o sus sales farmacéuticamente aceptables, que poseen una actividad inhibitoria de la quinasa CSF-1R y por consiguiente son útiles por su actividad anti cancerígena y por lo tanto en métodos de tratamiento del cuerpo humano o animal. La invención se refiere también a procedimientos para la fabricación de dichos compuestos químicos, a las composiciones farmacéuticas que los contienen y a su uso en la fabricación de medicamentos utilizados en la producción de un efecto anti cancerígeno en un animal de sangre caliente como el hombre.
UY0001031812A 2008-05-07 2009-05-06 Derivados de cinolina como inhibidores de csf-1 UY31812A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5118808P 2008-05-07 2008-05-07
US8289108P 2008-07-23 2008-07-23

Publications (1)

Publication Number Publication Date
UY31812A true UY31812A (es) 2010-01-05

Family

ID=40894839

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031812A UY31812A (es) 2008-05-07 2009-05-06 Derivados de cinolina como inhibidores de csf-1

Country Status (10)

Country Link
US (1) US20110190272A1 (es)
EP (1) EP2310375A1 (es)
JP (1) JP2011520804A (es)
CN (1) CN102089286A (es)
AR (1) AR071753A1 (es)
CL (1) CL2009001112A1 (es)
PE (1) PE20091848A1 (es)
TW (1) TW200948803A (es)
UY (1) UY31812A (es)
WO (1) WO2009136191A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110071004A (ko) * 2008-10-14 2011-06-27 액테리온 파마슈티칼 리미티드 페네틸아미드 유도체 및 이의 헤테로시클릭 유사체
CN104370825B (zh) * 2014-09-29 2017-04-19 人福医药集团股份公司 作为激酶抑制剂的取代杂环化合物及其制备方法和用途
WO2016115013A1 (en) * 2015-01-12 2016-07-21 Janssen Pharmaceutica Nv Cinnoline derivatives useful as cb-1 receptor inverse agonists
WO2021144360A1 (en) * 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8621425D0 (en) * 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
AU634880B2 (en) * 1990-03-28 1993-03-04 Otsuka Pharmaceutical Co., Ltd. Quinoline derivative, antiulcer drug containing the same, and production of said derivative
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
SE0101675D0 (sv) * 2001-05-11 2001-05-11 Astrazeneca Ab Novel composition
GB0322726D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
WO2006124996A2 (en) * 2005-05-17 2006-11-23 Supergen, Inc. Inhibitors of polo-like kinase-1
BRPI0710191A2 (pt) * 2006-04-14 2012-06-05 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, e, composição farmacêutica
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CL2008000191A1 (es) * 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
RU2509085C2 (ru) * 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение

Also Published As

Publication number Publication date
WO2009136191A1 (en) 2009-11-12
JP2011520804A (ja) 2011-07-21
CL2009001112A1 (es) 2010-03-05
US20110190272A1 (en) 2011-08-04
CN102089286A (zh) 2011-06-08
EP2310375A1 (en) 2011-04-20
PE20091848A1 (es) 2010-01-08
TW200948803A (en) 2009-12-01
AR071753A1 (es) 2010-07-14

Similar Documents

Publication Publication Date Title
UY30282A1 (es) Compuestos quimicos
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
ECSP099322A (es) Compuestos químicos
UY29300A1 (es) Compuestos quimicos
UY30094A1 (es) Compuestos químicos
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
NI201500123A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
UY30547A1 (es) Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones.
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY31281A1 (es) Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
DOP2011000218A (es) Derivados de sulfonamida
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
ECSP11010807A (es) Sales de los compuestos del inhibidor de vih

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20130123